260
Participants
Start Date
June 30, 2024
Primary Completion Date
December 31, 2025
Study Completion Date
January 31, 2026
DEX-PRESSIN
This group will receive vasopressin as the first-line vasopressor. DEX will be started after hemodynamic stabilization if the heart rate is \>90 beats per minute (bpm). NE infusion will be the second-line vasoactive drug.
Standard of Care
This group will receive conventional treatment according to the SSC 2021 guidelines. This group will receive vasopressin as the second line after NE and will not receive DEX.
Mansoura University
OTHER